<% (signals.list.current.rate).substr(0,7) %>
<% signal.analyst %>
<% signal.analyst %>
Last Updated: Apr 01, 2026 11:38:16 AM (GMT)
JAZZ: The current market price is 189.06. No percentage change is available as there is no previous price.
Support and Resistance Levels Support levels are 189.06, 189.06, and 189.06. Resistance levels are also at 189.06, 189.06, and 189.06. The pivot point is at 189.06.
Indicators RSI is currently at 100, indicating overbought conditions with a persistent history of 100. The ATR stands at 0.00458, showing low volatility. The Parabolic SAR is at 187.17054, indicating a bullish trend. MACD shows a value of 0.04961 with its signal at 0.07259, suggesting a potential bearish crossover. There is no data for ADX or Stochastics.
Market Sentiment With the price above the pivot point of 189.06 and strong RSI, a bullish trend is indicated.
JAZZ Signals & Technical Analysis
Market Sentiment
Trend Indicators
Oscillators
Moving Averages
Pivot
About (JAZZ) Jazz Pharmaceuticals plc
Company Background
Jazz Pharmaceuticals plc is a global biopharmaceutical company headquartered in Dublin, Ireland, with significant operations in the United States. Established in 2003, the company specializes in the development and commercialization of innovative medicines for patients with unmet medical needs, particularly in the areas of neurology, psychiatry, and oncology. Jazz’s dedication to science-led innovation has positioned it as a leader in the industry, focusing on both rare diseases and common conditions that significantly impact patients' quality of life.
Market Position
Listed on NASDAQ under the ticker symbol JAZZ, Jazz Pharmaceuticals has established a strong market presence, driven by a robust portfolio of therapies. The company is recognized for its pioneering work in sleep medicine with its flagship product, Xyrem (sodium oxybate), and its expansion into the oncology sector with innovative treatments that address complex cancers. As a key player in the biopharmaceutical field, Jazz frequently explores strategic partnerships and acquisitions to enhance its product offerings and broaden its market reach.
Key Financial Highlights
Jazz Pharmaceuticals has demonstrated significant financial growth and stability, consistently outperforming market expectations. For the fiscal year 2022, the company reported a revenue increase of 10% year-over-year, largely attributed to the strong performance of its leading products and the successful launch of new therapies. With a diversified revenue stream and a commitment to research and development, Jazz remains focused on advancing its pipeline, which includes several promising candidates in clinical trials. The company's strong balance sheet, coupled with a strategic approach to operational efficiency, positions Jazz well for future growth in the competitive biopharmaceutical landscape.
Industry Highlights
In the rapidly evolving biopharmaceutical industry, Jazz Pharmaceuticals is committed to leveraging cutting-edge research and technology to deliver innovative healthcare solutions. The company's focus on rare diseases and niche markets allows it to address significant unmet medical needs while maintaining a competitive edge. As healthcare continues to transform, Jazz’s proactive approach to drug development and market expansion reinforces its position as a key player in improving patient outcomes worldwide.
Related Stocks
Sidebar rates
- <% signal.pair %>
<% signals.active.Current.rate.substr(0,7) %>
